Gyre Therapeutics, Inc. (NASDAQ:GYRE) Short Interest Up 122.9% in May

Gyre Therapeutics, Inc. (NASDAQ:GYREGet Free Report) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totalling 169,600 shares, a growth of 122.9% from the April 30th total of 76,100 shares. Based on an average trading volume of 68,700 shares, the short-interest ratio is currently 2.5 days. Currently, 0.8% of the shares of the company are sold short.

Insiders Place Their Bets

In other Gyre Therapeutics news, Director Nassim Usman sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $14.13, for a total value of $282,600.00. Following the transaction, the director now owns 1,636 shares of the company’s stock, valued at $23,116.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.92% of the stock is currently owned by corporate insiders.

Gyre Therapeutics Stock Performance

NASDAQ GYRE traded up $0.46 during trading hours on Thursday, reaching $10.41. The company’s stock had a trading volume of 62,826 shares, compared to its average volume of 78,156. The business has a 50-day simple moving average of $15.28 and a 200 day simple moving average of $17.85. Gyre Therapeutics has a 52 week low of $3.15 and a 52 week high of $30.40.

Gyre Therapeutics (NASDAQ:GYREGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.04 EPS for the quarter. The firm had revenue of $27.17 million during the quarter. As a group, sell-side analysts forecast that Gyre Therapeutics will post -0.45 earnings per share for the current year.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.

See Also

Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with's FREE daily email newsletter.